Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 2 of 113, showing 5 Applications out of 564 total, starting on record 6, ending on 10

# Protocol No Study Title Investigator(s) & Site(s)

6.

ECCT/25/11/06   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr Maricianah Onono
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
3. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
 
View

7.

ECCT/25/11/05   MK-8527-011 Study
    A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis   
Principal Investigator(s)
1. Dr. Joshua Kimani
Site(s) in Kenya
1. Nyanza Reproductive Health Society (NRHS), UNIM Research and Training Centre (URTC) (Kisumu county)
2. Partners for Health and Development in Africa – Sex workers Outreach Program (PHDA – SWOP) Clinic- Nairobi, Kenya (Nairobi City county)
3. Kenya Impact Research and Development Organization (K-IRDO) (Kisumu county)
 
View

8.

ECCT/25/11/03   RSV IMPACT TRIAL
    A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants.   
Principal Investigator(s)
1. Nancy A. Otieno
2. Evans M. Ogoti
Site(s) in Kenya
Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1)
 
View

9.

ECCT/25/10/01   H06_04TP
    A Phase 2, open-label, single-center, long-term immunogenicity follow-up study of the GVGH altSonflex1-2-3 Shigella vaccine 1, 2 and 3 years   after vaccination in African children.   
Principal Investigator(s)
1. Deborah Chepngeno Langat
Site(s) in Kenya
KEMRI CRC WRP KERICHO
 
View

10.

ECCT/25/09/03   PRESERVE
    Partial breast re-irradiation using ultra hypofractionation (PRESERVE) Phase 2 multi-institutional study   
Principal Investigator(s)
1. Angela Waweru
Site(s) in Kenya
Aga Khan University Hospital
 
View